Special report: a try-it-all strategy for building trust in clinical trials; Civica Rx starts selling first generic drug for prostate cancer

Robert Winn's "district walks" are one of the cornerstones of an overarching strategy the Massey Cancer Center director calls "high tech, high touch." ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

The trust-builder: a cancer center director's try-it-all strategy for breaking the barriers between research and Black patients By Angus Chen Carlos Bernate for STAT Black residents had reason to distrust the hospital at Virginia Commonwealth University. Robert Winn is building trust any way he can. Read More STAT+: Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain By Ed Silverman Adobe "There are warped incentives in our drug distribution channel," said Antonio Ciaccia, who heads 46brooklyn Research. Read More STAT+: Serious liver side effects detour Amgen's effort to expand use of its KRAS-blocking lung cancer drug By Adam Feuerstein Mark J. Terrill/AP The study results are a setback for Amgen’s effort to craft new treatments involving its KRAS-targeting cancer drug called Lumakras. Read More Opinion: Triple-negative breast cancer highlights the need to act against health inequities By Maimah Karmo National Cancer Institute/Univ. of Pittsburgh Cancer Institute Triple-negative breast cancer tends to affect Black and Hispanic women. Too few of them are aware that it often develops before age 40. Read More STAT+: The Senate's drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences By Matthew Herper Molly Ferguson for STAT There’s almost no doubt drug pricing legislation like this will have some impact on pharma innovation. But the status quo was untenable. Read More Tuesday, August 9, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser